President and CEO
Ken Keller is currently President and CEO of American Regent, Inc. and President and CEO of Daiichi Sankyo, Inc. Ken has more than 30 years of experience in the pharmaceutical industry in general management, commercial, international and joint venture leadership, as well as chief operating officer experience in several therapeutic areas, including oncology, rheumatology, dermatology and primary care.
As President and CEO of American Regent Inc. and Daiichi Sankyo Inc., Ken leads all of Daiichi Sankyo Inc. North America businesses with over two thousand employees.
Prior to joining the Daiichi Sankyo Group, Mr. Keller was the President and Chief Operating Officer at Spectrum Pharmaceuticals. Under his leadership, Spectrum’s portfolio grew from two to four marketed products, and has effectively advanced a number of product candidates through pivotal studies.
Mr. Keller spent 21 years at Amgen. His most recent role was Vice President and General Manager, Bone Health Business Unit. Previously, he was responsible for the Inflammation Business Unit, which contributed more than $3 billion in revenue. During his career at Amgen, Mr. Keller was the general manager for four of the world's top-selling biologic medicines: Neupogen®, Neulasta®, Aranesp® and Enbrel®, total revenues exceeded $10B. He also has significant international experience as managing director for Amgen’s United Kingdom and Ireland Affiliate.
Mr. Keller holds a BS in Business from St. John’s University and an MBA from Loyola Marymount University.